Literature DB >> 30649303

Clinical outcomes, pharmacological treatment, and quality of life of patients with stable coronary artery diseases managed by cardiologists: 1-year results of the START study.

Leonardo De Luca1, Pier Luigi Temporelli2, Carmine Riccio3, Lucio Gonzini4, Lina Marinacci5, Sara Norma Tartaglione6, Paolo Costa7, Marino Scherillo8, Michele Senni9, Furio Colivicchi10, Michele Massimo Gulizia11.   

Abstract

AIMS: We evaluated the 1-year clinical events, pharmacological management, and quality of life in a contemporary cohort of stable coronary artery disease (CAD) patients managed by cardiologists. METHODS AND
RESULTS: START (STable Coronary Artery Diseases RegisTry) was a prospective, observational, nationwide study that enrolled 5070 stable CAD patients over 3 months in 183 cardiology centres in Italy. At 1 year, 4790 (94.5%) patients had data on vital status. Death occurred in 107 (2.2%) patients and the cause of death was cardiovascular in 41 (38.3%) of cases. Among the 4775 patients with follow-up data on clinical events available, a hospitalization due to cardiovascular and non-cardiovascular causes occurred in 523 (11.0%) and in 231 (4.8%) of cases, respectively. Over 60% of patients reported as 'no problems' in all domains (61.4-84.5%) of the EuroQoL quality of life 5D-5L questionnaire. Among the 3239 patients with clinical visit/telephone interview at follow-up, in whom optimal medical therapy (OMT; aspirin or thienopyridine, β-blocker, and statin) was prescribed at enrolment, 2971 (91.7%) were still receiving OMT at follow-up. At multivariable analysis, only increasing age (odds ratio 0.98; 95% confidence interval 0.97-0.99; P = 0.04) resulted as independent negative predictor of OMT persistence at 1 year from enrolment.
CONCLUSION: In this large, contemporary registry, stable CAD patients managed by cardiologists presented a high rate of clinical events at 1 year. Nevertheless, the persistence to OMT and quality of life appeared reasonable. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Outcome; Quality of life; Stable coronary artery disease; Treatment

Year:  2019        PMID: 30649303     DOI: 10.1093/ehjqcco/qcz002

Source DB:  PubMed          Journal:  Eur Heart J Qual Care Clin Outcomes        ISSN: 2058-1742


  4 in total

1.  Increased bodyweight and inadequate response to aspirin in individuals with coronary artery disease.

Authors:  Remo H M Furtado; Robert P Giugliano; Talia F Dalcoquio; Flavia B B Arantes; Carlos J D G Barbosa; Paulo R R Genestreti; André Franci; Fernando R Menezes; Carlos A K Nakashima; Marco A Scanavini Filho; Aline G Ferrari; Rocio Salsoso; Luciano M Baracioli; Jose C Nicolau
Journal:  J Thromb Thrombolysis       Date:  2019-08       Impact factor: 2.300

2.  Clinical Impact and Prognostic Role of Triglyceride to High-Density Lipoprotein Cholesterol Ratio in Patients With Chronic Coronary Syndromes at Very High Risk: Insights From the START Study.

Authors:  Leonardo De Luca; Pier Luigi Temporelli; Furio Colivicchi; Lucio Gonzini; Maria Luisa Fasano; Massimo Pantaleoni; Gabriella Greco; Fabrizio Oliva; Domenico Gabrielli; Michele Massimo Gulizia
Journal:  Front Cardiovasc Med       Date:  2022-04-13

3.  Fat-to-muscle ratio as a predictor for dyslipidaemia in transitional-age youth.

Authors:  Jia-Xing Zhang; Wen Li; Xiu-Juan Tao; Chen Chen; Qing-An Wang; Wan-Lu Liu; Chan Yang; Kai-Rong Wang; Jiang-Wei Qiu; Yi Zhao; Yu-Hong Zhang
Journal:  Lipids Health Dis       Date:  2022-09-19       Impact factor: 4.315

4.  P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials.

Authors:  Marco Valgimigli; Felice Gragnano; Mattia Branca; Anna Franzone; Usman Baber; Yangsoo Jang; Takeshi Kimura; Joo-Yong Hahn; Qiang Zhao; Stephan Windecker; Charles M Gibson; Byeong-Keuk Kim; Hirotoshi Watanabe; Young Bin Song; Yunpeng Zhu; Pascal Vranckx; Shamir Mehta; Sung-Jin Hong; Kenji Ando; Hyeon-Cheol Gwon; Patrick W Serruys; George D Dangas; Eùgene P McFadden; Dominick J Angiolillo; Dik Heg; Peter Jüni; Roxana Mehran
Journal:  BMJ       Date:  2021-06-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.